A cfDNA fragmentomics classifier for noninvasive differentiation of benign and malignant renal masses.
A blood-based test accurately identified kidney tumors in challenging cases, suggesting new possibilities for noninvasive cancer diagnosis.
This PubMed record reports that the classifier also demonstrated potential clinical utility in diagnostically challenging settings, including lipid-poor angiomyolipoma and oncocytoma, with 12 of 13 oncocytoma samples correctly classified in an independent cohort. It provides cohort study evidence relevant to Early cancer detection.
What the study was
- Study design
- Cohort study
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Molecular biomedicine
Why it surfaced
Conservative rapid triage based on the PubMed abstract and citation metadata; cohort study with early detection relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.